Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome

First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to <22 years) in Q4 2025, with enrollment advancing across ...
Business Wire

Broken String Biosciences Launches Catalyst Program to Shorten Gene Editing Therapy Development by Months

BOSTON & CAMBRIDGE, England--(BUSINESS WIRE)--Broken String Biosciences (“Broken String”), a leader in advancing gene editing safety, today opened its Catalyst Early Access Program (EAP) for ...
Nasdaq

Taysha Gene Therapies Highlights TSHA-102 Program Advancements for Rett Syndrome at 2025 IRSF Scientific Meeting

Taysha Gene Therapies, Inc. announced key updates on its TSHA-102 program, an investigational gene therapy for Rett syndrome, at the upcoming 2025 International Rett Syndrome Foundation Scientific ...
Seeking Alpha

Ocugen outlines 2025 milestones for gene therapy programs with BLA filings on track

CEO Shankar Musunuri highlighted advancements in Ocugen’s modifier gene therapy platform, specifically targeting three biologics license application (BLA) filings over the next three years. OCU400, ...

Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome

First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to Reached written alignment with FDA on inclusion of =3 months of safety data from ASPIRE trial evaluating TSHA-102 (N=3 ...